Vitamin D supplements may reduce the risk of long COVID symptoms, such as fatigue and brain fog, according to a recent study conducted by researchers at Mass General Brigham.
A new study suggests that vitamin D supplements could play a role in alleviating long COVID symptoms, which persist after the initial infection. Researchers at Mass General Brigham investigated whether high doses of vitamin D could affect COVID-19 outcomes, particularly the risk of developing long COVID, a condition characterized by lingering symptoms such as fatigue, shortness of breath, and brain fog. The findings were published in The Journal of Nutrition.
The randomized clinical trial involved 1,747 adults who had recently tested positive for COVID-19, along with 277 members of their households. Participants were assigned to receive either vitamin D3 supplements or a placebo for a duration of four weeks.
Dr. JoAnn Manson, the senior author of the study and a physician at Mass General Brigham, highlighted the potential benefits of vitamin D supplementation for long-term symptoms. “A key takeaway is that vitamin D supplementation looks promising for reducing the risk of developing long COVID but does not appear to affect the severity of the acute infection,” Manson stated.
While the study found that vitamin D supplementation did not significantly alter short-term outcomes, such as symptom severity or the need for hospital visits, a closer examination of participants who adhered to the supplement regimen revealed a noteworthy difference in lingering symptoms. Approximately 21% of those who took vitamin D reported at least one ongoing symptom eight weeks after infection, compared to 25% of participants who received a placebo.
“There’s been tremendous interest in whether vitamin D supplements can be of benefit in COVID, and this is one of the largest and most rigorous randomized trials on the subject,” Manson remarked in a press release. “While we didn’t find that high-dose vitamin D reduced COVID severity or hospitalizations, we observed a promising signal for long COVID that merits additional research,” she added.
Manson explained that vitamin D may influence longer-term complications due to its role in regulating inflammation within the body. However, the researchers acknowledged several limitations in the trial. The study had to be conducted remotely during the pandemic, and participants began taking vitamin D several days after their COVID diagnosis.
Ideally, Manson noted, supplementation should commence before infection or immediately following diagnosis. She emphasized the need for larger studies to confirm whether vitamin D could effectively reduce the risk or severity of long COVID symptoms.
Researchers are planning additional trials to further explore the potential of vitamin D supplementation in treating individuals already experiencing long COVID.
These findings provide a promising avenue for future research and may offer hope for those grappling with the long-term effects of COVID-19, according to Fox News.